Dogwood Therapeutics licenses SP16 for CIPN in all-stock deal; NCI funds Phase 1b

Dogwood Therapeutics, Inc.

Royalty-free global license from Serpin Pharma for SP16, a first-in-class LRP1 agonist targeting chemotherapy-induced peripheral neuropathy (CIPN).
Consideration: 382,034 common shares + 179.1878 Series A-2 Preferred shares (convert 1:10,000), representing 7.31% fully diluted.
Phase 1b CIPN study fully funded by NCI; patient enrollment projected first half 2026.
Halneuron Phase 2b ongoing (80 patients randomized); interim data from 90-100 patients expected December 2025.
Support agreements with Serpin, Tungsten, and Sealbond to vote for stockholder approval of preferred stock conversions.

item 1.01item 5.03item 3.02item 3.03item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.